TY  - JOUR
A1  - Loibl, Sibylle
A1  - Furlanetto, Jenny
T1  - Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
T2  - The Breast
N2  - CDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer. All studies conducted in metastatic breast cancer showed a benefit in delaying progression when added to standard endocrine therapy, regardless of therapy line, pretreatment, menopausal status, site of metastasis, CDK4/6 inhibitor used and associated endocrine therapy. A benefit in overall survival has also been demonstrated. In early breast cancer, only the MonarchE study has shown an improved invasive disease-free survival with abemaciclib taken for 2 years, whereas the Penelope-B did not meet the primary endpoint and the PALLAS study was terminated early for futility. Studies conducted in the neoadjuvant setting might help to explain the discordant results.
KW  - CDK4/6 inhibitors
KW  - Endocrine therapy
KW  - Hormone receptor positive breast cancer
KW  - Early setting
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/78423
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-784237
SN  - 0960-9776
VL  - 620.2022
SP  - S70
EP  - S79
PB  - Elsevier
CY  - Amsterdam
ER  -